1.Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12–23.
2.zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009;384(2):260–265.
3.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
4.Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med. 2011;53 Suppl 1:S12–21.
5.Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–79.
6.Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S3/1–10.
7.Nicol AF, Andrade CV, Russomano FB, Rodrigues LL, Oliveira NS, Provance DW, Jr. HPV vaccines: a controversial issue? Braz J Med Biol Res. 2016;49(5):e5060.
8.de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. The Lancet Infectious Diseases. 2007;7(7):453–459.
9.Jalilvand S, Shoja Z, Nourijelyani K, Tohidi HR, Hamkar R. Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination. J Med Virol. 2015;87(2):287–295.
10.Chelimo C, Wouldes TA, Cameron LD, Elwood JM. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J Infect. 2013;66(3):207–217.
11.Lim AW, Landy R, Castanon A, Hollingworth A, Hamilton W, Dudding N, Sasieni P. Cytology in the diagnosis of cervical cancer in symptomatic young women: a retrospective review. Br J Gen Pract. 2016;66(653):e871-e879.
12.Kietpeerakool C, Cheewakriangkrai C, Suprasert P, Srisomboon J. Feasibility of the ‘see and treat’ approach in management of women with ‘atypical squamous cell, cannot exclude high-grade squamous intraepithelial lesion’ smears. J Obstet Gynaecol Res. 2009;35(3):507–513.
13.Aue-Aungkul A PS, Natprathan A, Srisomboon J, Kietpeerakool C. “See and Treat” Approach is Appropriate in Women with Highgrade Lesions on either Cervical Cytology or Colposcopy. Asian Pacific Journal of Cancer Prevention Apjcp. 2011;12(7):1723–1726.
14.Uijterwaal MH, Polman NJ, Van Kemenade FJ, Van Den Haselkamp S, Witte BI, Rijkaart D, Berkhof J, Snijders PJ, Meijer CJ. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing. Cancer Prev Res (Phila). 2015;8(6):502–508.
15.Tsedenbal B, Yoshida T, Enkhbat B, Gotov U, Sharkhuu E, Saio M, Fukuda T. Human papillomavirus genotyping among women with cervical abnormalities in Ulaanbaatar, Mongolia. Int J Infect Dis. 2018;77:8–13.
16.Krashias G, Koptides D, Christodoulou C. HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities. BMC Infect Dis. 2017;17(1):346.
17.Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349–2359.
18.Zhao X-L, Hu S-Y, Zhang Q, Dong L, Feng R-M, Han R, Zhao F-H. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population. Journal of Gynecologic Oncology. 2017;28(4).
19.Zhong T-Y, Zhou J-C, Hu R, Fan X-N, Xie X-Y, Liu Z-X, Lin M, Chen Y-G, Hu X-M, Wang W-H, Li L, Xiao H-P. Prevalence of human papillomavirus infection among 71,435 women in Jiangxi Province, China. Journal of Infection and Public Health. 2017;10(6):783–788.
20.Zhao P, Liu S, Zhong Z, Hou J, Lin L, Weng R, Su L, Lei N, Hou T, Yang H. Prevalence and genotype distribution of human papillomavirus infection among women in northeastern Guangdong Province of China. BMC Infect Dis. 2018;18(1):204.
21.Baloch Z, Li Y, Yuan T, Feng Y, Liu Y, Tai W, Liu L, Wang B, Zhang AM, Wu X, Xia X. Epidemiologic characterization of human papillomavirus (HPV) infection in various regions of Yunnan Province of China. BMC Infect Dis. 2016;16:228.
22.X. Castellsague SdS TA. HPV and cervical cancer in the 2007 report. Vaccine. 2007;25 Suppl 3:C1-C26.
23.Vargas H, Sanchez JP, Guerrero ML, Ortiz LT, Rodriguez DM, Amaya J, Diaz LP, Gomez SL, Golijow C. Type-Specific Identification of Genital Human Papillomavirus Infection in Women with Cytological Abnormality. Acta Cytol. 2016;60(3):211–216.
24.Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer. 2012;130(3):641–652.
25.Li J, Huang R, Schmidt JE, Qiao Y-L. Epidemiological Features of Human Papillomavirus (HPV) Infection among Women Living in Mainland China. Asian Pacific Journal of Cancer Prevention. 2013;14(7):4015–4023.
26.Baloch Z, Yasmeen N, Li Y, Ma K, Wu X, Yang SH, Xia X. Prevalence and risk factors for human papillomavirus infection among Chinese ethnic women in southern of Yunnan, China. Braz J Infect Dis. 2017;21(3):325–332.
27.Zou L BYP, Li N, Dai M, Ma CP, Zhang Y Z, Liu X F, Feinleib M, Qiao Y L. Life-style and genital human papillomavirus in a cross-sectional survey in Shanxi Province, China. Asian Pacific Journal of Cancer Prevention Apjcp. 2011;12(3):781–786.
28.Kaushic C, Roth KL, Anipindi V, Xiu F. Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses. J Reprod Immunol. 2011;88(2):204–209.
29.Wang J T GES, Cheng Y Y, Yan J W, Ding L. Analysis on synergistic action between estrogen, progesterone and human papillomaviruses in cervical cancer. Zhonghua Liu Xing Bing Xue Za Zhi. 2005;26(5):370–373.
30.Wang J T GES, Ding L, Cheng Y Y, Yan J W. Association between endogenous hormones, hormone receptors and cervical cancer. Chinese journal of oncology. 2006;28(7):494–497.
31.Wang J T DL, Jiang S W, Hao J X, Zhao W M, Zhou Q, Yang Z K, Zhang L. Folate Deficiency and Aberrant Expression of DNA Methyltransferase 1 were Associated with Cervical Cancerization. Curr Pharm Des. 2014;20(11):1639–1646.
32.Mongelos P, Mendoza LP, Rodriguez-Riveros I, Castro A, Gimenez G, Araujo P, Paez M, Castro W, Basiletti J, Gonzalez J, Echague G, Diaz V, Laspina F, Ever S, Marecos R, Deluca G, Picconi MA. Distribution of human papillomavirus (HPV) genotypes and bacterial vaginosis presence in cervical samples from Paraguayan indigenous. Int J Infect Dis. 2015;39:44–49.
33.McInerney KA, Hatch EE, Wesselink AK, Mikkelsen EM, Rothman KJ, Perkins RB, Wise LA. The Effect of Vaccination Against Human Papillomavirus on Fecundability. Paediatr Perinat Epidemiol. 2017;31(6):531–536.